GlassScriptPhysician profile
Kevin A Davis
NPI 1033452990
$2,005.06
in general payments reported to CMS, 2019-2025
19 companies · $741 in 2025
The $741 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.09 · 2021: $41.47 · 2022: $258 · 2023: $313 · 2024: $637 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595 · Education: $95.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,594.82 |
| Education | $95.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $411.68 | 2022-2025 | Biktarvy |
| Viiv Healthcare Company | $410.93 | 2022-2025 | Cabenuva, Dovato |
| Insmed, INC. | $332.79 | 2023-2025 | Arikayce |
| Astellas Pharma US INC | $156.74 | 2022-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $105.98 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Paratek Pharmaceuticals, INC. | $94.48 | 2019-2025 | Nuzyra |
| Pfizer INC. | $92.23 | 2023-2025 | |
| Abbvie INC. | $75.93 | 2025 | |
| Melinta Therapeutics, LLC | $74.44 | 2024-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Merck Sharp & Dohme LLC | $59.50 | 2025 | Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.02 | 2022-2024 | Ofev |
| Novo Nordisk INC | $31.21 | 2021-2023 | |
| Exact Sciences Corporation | $28.41 | 2023 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $17.96 | 2022 | |
| Sumitomo Pharma America, INC. | $17.04 | 2024 | Gemtesa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $16.04 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.43 | 2024 | Trulance, Xifaxan |
| Shionogi INC | $13.20 | 2021 | |
| Amgen INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.